POXEL SA announced that the FDA has granted Fast Track Designation to PXL770 for the treatment of patients with adrenomyeloneuropathy, the most common form of X-linked adrenoleukodystrophy.
[Poxel SA]
Sorry, but the selected Zotpress account can't be found.